[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advance-pancreatic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advance-pancreatic-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100601405","phase-2-ql1706lenvatinibag-regimen-as-first-line-treatment-for-advanced-metastatic-pancreatic-cancer-100601405",false,"NCT07110064","QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","Iparomlimab and Tuvonralimab Injection (QL1706) in Combination With Lenvatinib and AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer:A Prospective, Single-Arm, Multicenter, Phase II Clinical Study","Inclusion Criteria:\n\n* a. Age ≥18 years, ECOG performance status ≤2, and expected survival of ≥3 months.\n* b. Patients with histologically or cytologically confirmed advanced metastatic pancreatic cancer.\n* c. At least one measurable lesion according to RECIST 1.1 criteria;\n* d. No prior anti-tumor treatment of any kind.\n* e. Patients must meet the following hematological criteria: e1. White blood cell count (WBC) ≥3.0×10\\^9\u002FL; e2. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; e3. Hemoglobin (HB) ≥90 g\u002FL; e4. Platelet count (PLT) ≥75×10\\^9\u002FL; e5. Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); e6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; if there is liver metastasis, then ALT and AST ≤5×ULN; e7. Serum creatinine (Cr) ≤1×ULN or creatinine clearance (CCr) ≥50 ml\u002Fmin;\n* f. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).\n* g. Patients of childbearing potential must take appropriate protective measures (contraception or other methods of fertility control) before enrollment and during the study.\n* h. Willingness to participate in the study, with signed informed consent, good compliance, and cooperation with follow-up; able to adhere to the study protocol and follow-up procedures.\n\nExclusion Criteria:\n\n* a. Prior receipt of systemic anti-tumor treatment, such as chemotherapy, radiotherapy, or other anti-tumor treatments.\n* b. Participation in another drug clinical trial within the past 4 weeks.\n* c. Subjects who, in the investigator's judgment, have the opportunity for surgery or are potentially operable (subjects who voluntarily forgo surgical treatment may be enrolled after investigator assessment and agreement).\n* d. Subjects with moderate ascites requiring drainage (except for those with minimal ascites shown on imaging without symptoms).\n* e. Known symptomatic central nervous system metastases and\u002For carcinomatous meningitis.\n* f. History of other primary malignancies, except for the following: 1) Malignancies that have been in complete remission for at least 2 years prior to enrollment and do not require other treatments during the study; 2) Non-melanoma skin cancer or malignant lentigo that has been adequately treated and shows no evidence of disease recurrence; 3) Carcinoma in situ that has been adequately treated and shows no evidence of disease recurrence.\n* g. Patients with autoimmune diseases or immune deficiencies who are being treated with immunosuppressive drugs.\n* h. Patients with a tendency to bleed.\n* i. Pregnant or breastfeeding women. Women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.\n* j. Drug abuse, or clinical, psychological, or social factors that may affect informed consent or study implementation.\n* k. Subjects who may be allergic to epaltrastide (QL1706), lenvatinib, albumin-bound paclitaxel, or gemcitabine.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 80 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.",[26],"Advance Pancreatic Cancer","RECRUITING","2025-12-28",{"date":30,"type":31},"2026-01-02","ACTUAL",{"date":33,"type":31},"2025-09-03",{"date":35,"type":20},"2028-08-31",{"name":37,"class":38},"Du Juan","OTHER"]